Julien Dômont

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

José Baselga, Ian Bradbury, Holger Eidtmann et al. · The Lancet · 2012 · 1.3K citations · Full text

Breast Oncology, Oncology, Pathology +5

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Egfrviii-expressing Glioblastoma, Neuro-oncology, Act Iv +10

Lomustine and Bevacizumab in Progressive Glioblastoma

Wolfgang Wick, Thierry Gorlia, Martin Bendszus et al. · New England Journal of Medicine · 2017 · 949 citations · Full text

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

Thomas Bachelot, Gilles Romieu, Mario Campone et al. · The Lancet Oncology · 2012 · 733 citations

Breast Oncology, Brain Metastases, Medicine +8

Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients

Fabrice Denis, Claire Lethrosne, N. Pourel et al. · JNCI Journal of the National Cancer Institute · 2017 · 493 citations · Full text